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Estrogen ~ding protein activities were determined 
in the cytosoJirom adult male Buffalo rat liver and 
Morris hepatomb 7777. Estrogen receptors were pre-
pared using the protamine sulfate precipitation 
technique of Chamness. The ability of various unla-
beled steroids competing with eHJestradiol was ex-
amined to establish the binding specificity. Estradi-
ol binding in Morris hepatoma 7777 cytosol was 
greatly decreased compared with that present in 
hepatic cytosol prepared from normal rat liver. The 
receptor concentration expressed as femtomoles per 
milligram of cytoplasmic protein was 31.1 ± 2.9 SD 
for normal rat liver and 0.41 ± 0.88 SD for the 
hepatoma. Gel filtration chromatography revealed 
the presence of an estrogen binder in hepatoma 
cytosol which was not present in either normal liver 
or in the protamine sulfate precipitates of hepatoma 
cytosol. The molecular weight, binding specificity. 
and precipitation of this protein by specific antiser-
um suggests that it is a-fetoprotein. 
The liver is a steroid-responsive organ both in male 
and female animals. Moreover, in both sexes many 
biochemical events occur that are dependent, at least 
in part, upon steroid hormone action. These include 
the transport of hydrophobic materials by various 
plasma proteins synthesized by the liver, such as sex 
steroid-binding globulin (1), the production of impor-
tant circulating substances such as renin substrate 
(2,3), and the production and secretion of various 
circulating proteins such as ceruloplasmin (4). 
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After the original discovery of estrogen receptor in 
the liver (5-12), many attempts have been made to 
define a possible role for steroid hormones; particu-
larly estrogens, in the pathogenesis of various hepat-
ic d.iseases. This is particularly true for diseases such 
as hepatic adenoma (13.14), focal nodular hyperpla-
sia (15-18), hepatoma, and angiosarcoma (19-22), 
although the relationship between estrogens and 
focal nodular hyperplasia has been questioned. re-
cently (23). Each of these hepatic disorders has been 
associated, at least circumstantially, with the long-
term use of steroidal agents such as estrogens, andro-
gens, or prednisone for any of a variety of clinical 
indications. 
The present study is a report on the identification 
and quantitation of estrogen receptors in cytosol 
obtained from normal rat liver and from the Morris 
hepatoma 7777. The latter is a well-differentiated 
trabecular carcinoma (24) and was originally in-
duced by feeding N-2-fluorenylphthalmic acid (FPA) 
to Buffalo strain inbred rats. It is a fast growing 
"minimal deviation" tumor which grows well in 
both sexes, although it was maintained primarily in 
male rats in our laboratory. 
Methods 
Tissue 
Livers from adult male Buffalo rats were used (250 
g). The animals were killed by decapitation and the livers 
were removed, washed, and placed immediately in iced 
saline solution for later processing. Morris hepatomas 
7777 in Buffalo rats were transplanted subcutaneously to 
Buffalo recipients. The tumors were removed for the 
Abbreviations used in this paper: AFP. a-fetoprotein; BSA. 
bovine serurnalbumin; DHT. 5.a-dihydrotestosterone; DES. dieth-
ylstilbesterol; E
" 
estrone; E2• estradiol; E3• estriol; FPA. N-2-
fluorenylphthalmic acid; 2-0Me-E2 • 2-methoxyestradiol. 
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preparation of cytosol when the tumor weight was judged 
to be equal to liver weight (-10 g). 
Materials 
Estrone (E l ), estradiol (E2), estriol (E3), and 2-meth-
oxyestradiol (2-OMe-E2), were purchased from Steraloids, 
Wilton, N.H. Diethylstilbesterol (DES), testosterone, 5,a-
dihydrotestosterone (DlIT) , progesterone, bovine serum 
albumin (BSA), standards for gel filtration chromatography, 
and protamine sulfate were purchased from Sigma Chemical 
Company, St. Louis, Mo. Norit A and dextran C were 
obtained from Fisher Scientific Company, Pittsburgh, Pa. 
Protein A - Sepharose was obtained from Pharmacia Fine 
Chemicals, Piscataway, N.J.; rabbit antiserum to mouse a-
fetoprotein and goat antiserum to rabbit IgG were purchased 
from Miles Laboratories, Elkhart, Ind. [2,4,6,7,16,17 3HJEs-
tradiol, [3HIEz, 151 Cilmmol, was obtained from New Eng-
land Nuclear, Boston. Mass. The radiolabeled material used 
in these studies was assayed periodically for purity by thin-
layer chromatography on silica gel G in ethyl acetatelhexanel 
ethanol (85:10:5), and was used only if purity as deter-
mined by radiolabel migration was 95%. 
Preparation of Cytosol 
Approximately 10 g of tissue was used for each 
assay. All procedures were performed at DOC. The liver was 
minced and homogenized with a Brinkmann polytron 
(Brinkmann Instruments, Inc., Westbury, N.Y.) in 2 vol-
umes of TED buffer [0.01 M Tris-HCI, 1.5 mM ethylenedi-
aminetetraacetate (EDT A), 0.01 mM dithiothreitol, pH 
7.41. The resultant homogenate was centrifuged for 60 min 
at 105,000 g. The supernate was removed carefully to 
prevent lipid contamination and treated with Norit A and 
dextran C according to the technique of Chamness (8,25). 
The final protein concentration in the cytosol samples 
prepared was 15-25 mg/ml. Immediately before use, the 
cytosol was diluted to a final protein concentration of 5 
mg/ml. 
Protamine Sulfate Assay 
Receptors were prepared using the protamine sul-
fate precipitation technique of Chamness et al. (8,25), 
which precludes contamination due to binding of steroid 
to the moderate-affinity high-capacity male specific estro-
gen binder (12). Cytosol (0.2 ml) pretreated with dextran-
coated charcoal and protamine sulfate (0.2 ml) solution 
(1.5 mg/ml in TED buffer) were combined in multiple 
replicate tubes and mixed briefly. After standing for 5 min 
at DoC, the reaction tubes were centrifuged at 800 g for 10 
min and the supernate was removed by suction. A 250-MI 
aliquot of radioactive steroid solution, with or without 
unlabeled hormone, was then added to each tube. After 
incubation for 18 h at DoC, the supernate was removed and 
the precipitate in each tube was washed with three 2-ml 
aliquots of cold TED buffer. The precipitate, at the bottom 
of the reaction tube. was dropped in a scintillation vial 
E2 BINDING AND EXPERIMENTAL HEPATOMAS 1411 
with 2 ml of absolute ethanol and mixed for 1 h. After this 
time the bottoms of the test tubes were removed and 10 ml 
of Instagel (Packard Instrument Company, Inc., Downers 
Grove, Ill.) was added. 
Binding Studies 
Protamine sulfate precipitates of 200-MI aliquots of 
hepatic or hepatoma cytosol were prepared and incubated 
with several concentrations of [3HIEz over a range of 0.15-
3 nM in the absence (total binding) and presence (nonspe-
cific binding) of 100-fold excess of unlabeled E2 for 18 hat 
DoC. Specific binding was obtained by subtracting nonspe-
cific binding from total binding. Scatchard analysis (26) 
was performed in the specific binding values. The slope 
and y-intercept of the apparent linear relationship were 
determined by use of the unweighted linear regression 
program of the TE 55 calculator (Texas Instruments, Hous-
ton, Tex.). In other studies to assess specificity of binding, 
a single saturating concentration (1.5 nM) of [3HIE2 was 
used in the presence and absence of loo-fold excess 
concentration of various unlabeled hormones. including 
E2, DES, Elo progesterone, testosterone, and DHT. 
Gel Filtration Chromatography 
Gel filtration chromatography of cytosolic proteins 
was carried out on Sephadex G-100 in Tris-EDTA buffer 
(0.01 M Tris HCI + 1.5 mM EDTA, pH 7.4). Cytosol (4 ml) 
from hepatoma was incubated with 2 nM [3H]E z for 2 h 
before chromatography. A 400-MI aliquot was removed 
from each 2.5-ml fraction to determine the (3HIE2 content. 
Cytosol from normal male liver was chromatographed and 
[lH]E2 binding activity was detected after chromatography 
by incubating 200 MI of each fraction with 5 nM [3HIE2 for 
2 h as described previously (12). The column (2.4 x 45 cm) 
was previously calibrated with blue dextran, BSA, ovalbu-
min, trypsinogen. and myoglobin and the molecular 
weights of the [3H1E2 binding proteins were estimated (27). 
In other studies on hepatoma, unlabeled cytosol was 
chromatographed and the [3H1E2 binding activity in each 
fraction was detected as described previously with un-
bound steroid being removed by dextran-charcoal treat-
ment (12). 
Immunoprecipitation Studies 
Protein A-Sepharose was washed and coupled ac-
cording to the manufacturer's recommendations to either 
rabbit antibodies against mouse a-fetoprotein (anti-AFP), 
or to goat antibodies against rabbit immunoglobulin G, the 
latter being used as a control preparation. Each prepara-
tion was stored as a slurry in TED buffer, 1 volume resin to 
7 volumes buffer. Serum from normal and hepatoma-
bearing animals, cytosol from normal male rat liver, liver 
of tumor-bearing hosts, and hepatoma were tested for 
estrogen binding activity by incubating aliquots (200 MI) of 
each with 5 nM [3H)E2 for 2 h at DoC. Unbound steroid was 
removed with dextran-coated charcoal (12). Serum from 
host animals and hepatoma cytosol were diluted until 
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Figure 1. Specific binding of the [3H]E2 by cytosol of the normal 
male rat liver. Aliquots (200 ~F of whole cytosol (5 
mglml) precipitated with protamine sulfate were incu-
bated with six different concentrations of [3HlE2 (0.15-
3 nM) for 18 h at O°C in the presence and absence of 
100-fold unlabeled E2• Specific binding was calculated 
by subtracting nonspecific binding from total binding. 
Each point is the average of triplicate determinations. 
Closed circles represent total binding, open circles 
nonspecific binding, triangles specific binding. 
binding activity reached 50%-60% of the [3H1E2 added, 
typically 1: 500 for serum and 1: 100 for cytosol. Normal 
rat and host liver cytosol were usually tested without 
dilution in order to detect low levels of immunoprecipita-
ble estrogen binding. Normal rat serum had no detectable 
estrogen binding activity. The appropriate dilution of 
serum or cytosol was then treated with an amount of anti-
AFP-Protein A-Sepharose slurry predetermined to result 
in maximum efficiency of precipitation, usually 0.5 ml. or 
an equivalent volume of control antiserum-Protein A-
Sepharose slurry for 1 h at O°C. The resin was removed by 
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Figure 2. Scatchard plot analysis of specific ['H]E2 binding in 
protamine sulfate precipitates of whole rat male liver 
cytosol. Aliquots (200 ~fF of whole cytosol were precip-
itated with protamine sulfate Bnd were incubated with 
six different concentrations of [3H]E2 (0.15-3 nM) for 
18 h at Ooc in the presence and absence of tOO-fold 
unlabeled E2 • 
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Figure 3. Specific binding of ['HJE2 by cytosol from adult male 
rats and Morris hepatoma 7777. Aliquots (200 JoLI) of 
whole cytosol (5 mglml) were precipitated with prot-
amine sulfate and were incubated with 1.5 mM of 
[3H]E2 in the presence or absence of tOO-fold unlabeled 
E2 • Specific binding was calculated by subtracting 
nonspeCific binding from total binding and was ex-
pressed as femtomoles per milligram of cytosol protein. 
p < 0.001. 
centrifugation and 200 iJ.I of each supernate was then 
tested for [3H1E2 binding activity as detailed previously in 
this section. 
Auxiliary Methods 
Protein concentration of cytosol was determined by 
the method of Lowry (28) using BSA as a standard. 
Radioactivity content of samples was determined in a 
Packard Tri-carb liquid scintillation spectrometer (Pack-
ard Instrument Co., Inc., Downers Grove, Ill.) Multiple 
results were expressed as mean ± SD and statistical 
analysis was performed using Student's nonpaired t-test. 
Results 
A typical binding curve obtained using the 
protamine sulfate technique for isolating cytoplas-
mic estradiol receptors from normal adult male rat 
liver is shown in Figure 1. Binding is saturable and 
of limited capacity. Figure 2 demonstrates a plot of 
the specific binding data using the method of Scat-
chard for analysis. A single class of binding (recep-
tor) molecules for estradiol with a uniform affinity 
was found (r = 0.99). In this particular experiment, 
the binding capacity was determined to be 35.8 fmol 
E2/mg protein and the Kd was determined to be 
4.42 x 10-10 M. Next, the level of estrogen receptors 
was assessed in several normal livers and in hepato-
ma tissue as described in Figures 1 and 2. Figure 3 
shows the specific binding of normal male rat liver 
(six samples) and that of Morris hepatoma 7777 (six 
samples). In four of the hepatomas the estrogen 
receptors were not found, that is, no specific binding 
was detectable. Two other hepatomas contained 
small amounts of estrogen receptor (0.26 and 2.2 
fmol/mg protein), much less than that detected in the 
normal liver. Other samples of hepatoma cytosol 
have been tested for retention on heparin-Sepharose, 
an affinity resin for steroid receptors; no estrogen 
binding activity was retained by this resin. 
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Figure 4. Specificity of binding to cytosolic proteins in male rat 
liver cytosol. Aliquots (200 ILl) of whole male rat liver 
cytosol were precipitated with protamine sulfate and 
were incubated with 1.5 nM [3H1E2 in the presence and 
absence of loo-fold excess of competing substance fa)' 
18 h at D·C. Each bar represents triplicate determina-
tions. 
To establish that the binding of the labeled estro-
gen in these studies was specific, the ability of 
various unlabeled steroids to compete with labeled 
estradiol was determined. The data shown in Figure 
4 demonstrate that the binding was specific for 
estrogens. Thus. [3H]E2 binding was not inhibited by 
testosterone. DHT. and progesterone. 
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Figure 5. Gel filtration chromatography of estrogen binding pro-
teins from male rat liver and Morris hepatoma 7777 
cytosol. Cytosol (4 ml) from normal liver (open circJes) 
was chromatographed on Sephadex G-IOO and estrogen 
binders were detected as indicated in Methods. Hepa-
toma (open circJes) cytosol was incubated for 2 h with 
2 nM [3H1E2 before chromatography on Sephadex G-
100. A 400-111 aliquot of each fraction was assayed for 
[3H1E2 content. Markers used to calibrate the column 
included blue dextran (Vo); bovine serum albumin (B). 
68.000; ovalbumin (0). 43.000; trypsinogen (n. 24.000; 
myoglobin (M). 17.000. 
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Figure 6. Specificity of binding to hepatoma estrogen binder. 
Fractions 33-35 were pooled from an experiment iden-
tical to that illustrated in Figure 5 except that the 
hepatoma cytosol was not labeled with [3H1E2 before 
chromatography; instead. each fraction was tested for 
[3H1Ez binding activity as indicated in Methods. The 
pooled fractions were tested for specifiCity by incubat-
ing with 5 nM [3H1Ez in the absence or presence of a 
100-fold excess of the potentially competing substance 
for 16 hat O·C. In one experiment. the pooled fractions 
were labeled with PH1Ez as above. except that after 
incubation and dextran-coated charcoal treatment. the 
sample was treated with protamine sulfate and the 
supernatant estrogen binding activity was determined. 
While protamine sulfate precipitation of hepatoma 
cytosol resulted in the detection of little or no 
estrogen receptor. estrogen binding studies in whole 
hepatoma cytosol revealed the presence of a high-
capacity estrogen binder. Binding studies show that 
this protein has a Kd for E2 of 5 x 10-8 M, indicating 
moderate affinity, and has a very high E2 binding 
capacity, 20 pmollmg cytosol protein (data not 
shown). 
When whole cytosol from normal liver and hepa-
toma were tested for estrogen binder content using 
gel filtration chromatography, the results were strik-
ingly different for these two tissues. As shown in 
Figure 5, normal rat liver has two [3H]E2 binding 
species. The first, eluting in the void volume of the 
column, has been characterized extensively as the 
hepatic estrogen receptor (12). The second, eluting 
from the column at a position consistent with a 
molecular weight of 25,000 is the hepatic male 
specific estrogen binder (MEB) described previously 
(12). Protamine sulfate precipitates the receptor but 
not the MEB (12). In contrast, the hepatoma contains 
neither the receptor nor the MEB, but instead con-
tains a unique estrogen binder which elutes as a 
species of -70,000 molecular weight. Further analy-
sis of this material pooled from fractions 34-36 after 
Sephadex G-100 chromatography reveals that unla-
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Table 1. Immunoprecipitation of eHJE2 Binding 
Activity in Hepatoma. Serum. and Normal 
Liver 
Preparation Dilution 
Hepatoma cytosol 1:100 
Host liver cytosol Undiluted 
Host serum 1:500 
Normal liver cytosol Undiluted 
[3H1E2 binding activity 
remaining 
Control AFP-
antiserumo antiserum 
(%) (%) 
100 17.6 
100 73.1 
100 23.9 
100 98.6 
AFP = a-fetoprotein. a Values for control serum-treated samples 
were set at 100%; these values were within 1: 10% of values of 
[3H1E2 binding in samples that were not treated with any Protein 
A-antibody resin. but were instead diluted with an appropriate 
volume of buffer. 
beled DES does not compete for [3H]E2 binding to 
this protein (Figure 6). Diethylstilbesterol. however. 
is very effective in competing for [3H]E2 binding to 
the receptor of normal liver as shown in Figure 4. 
suggesting that the protein which is present in hepa-
toma cytosol is not an altered form of the receptor. In 
addition. the specificity of the hepatoma estrogen 
binder differs from the MEB in that neither E3 nor 
2-0Me-E2 competes for [3H]E2 binding to the hepato-
ma protein; both of these substances are avid com-
petitors of [3H]E2 binding to MEB (12. manuscript in 
preparation). Furthermore, while protamine sulfate 
effectively precipitates the receptor of normal liver. 
it does not precipitate this hepatoma estrogen binder 
(Figure 6). 
A protein known to bind estrogen with similar 
affinity and specificity. and of a molecular size 
similar to the estrogen binder in hepatoma is a-
fetoprotein (AFP) (29). Therefore. we treated cytosol 
from normal and host liver as well as from hepatoma 
with antiserum to AFP; the results are shown in 
Table 1. Treatment of hepatoma cytosol with anti-
AFP results in removal of most of the estrogen 
binding activity (82.4%). whereas control antiserum 
had no effect. Undiluted host liver cytosol contains 
some immunoprecipitable E2 binding activity. prob-
ably as a result of serum contamination, as the serum 
of the host animal contains large quantities of AFP 
activity. Normal rat liver cytosol, undiluted, or at a 
1: 10 dilution (not shown), demonstrated no loss of 
[3H]E2 binding activity in the presence of either 
antiserum. 
Discussion 
The tumor-inducing potential of hormones in 
endocrine-related organs of experimental animals 
has been well demonstrated. Ever since Eisenfeld et 
GASTROENTEROLOGY Vol. 86. No. 6 
a1. (5,11) initially reported the presence of specific 
estradiol binding sites in the hepatic cytosol of adult 
female and male rats, and the subsequent demonstra-
tion of the presence of a molecule described as an 
androgen receptor in the same tissue by Milin et a1. 
(30). many research teams (31-34) have attempted to 
determine the relationship between hepatic steroid 
binding and the development of benign and malig-
nant hepatic neoplasms. 
In 1973, Baum et a1. (13) suggested a relationship 
between benign hepatic tumors and focal nodular 
hyperplasia and estrogen use in women who had a 
history of prior oral contraceptive use. In contrast to 
the usual relatively benign nature of contraceptive-
(estrogenic) induced tumors, liver tumors associated 
with the use of anabolic steroids are usually malig-
nant, especially when the androgen content of the 
hormonal preparation is high (35-37). 
At the present time, anabolic. androgenic, and 
estrogenic hormones are used widely for a variety of 
clinical indications. Because of this widespread use, 
numerous experiments have been performed to de-
fine the role of steroids, especially estrogens, in the 
pathogenesis of liver cell tumors. As a result of such 
studies, some authors have suggested that estrogens 
are carcinogenic (31,33,34). For example, in animals 
given various preparations of estrogens and proges-
tational agents, the liver tumor occurrence rate can 
be varied from 0% to 60% depending on the dose, 
agents given, and the time of exposure (34). 
Other authors have suggested that estrogens pro-
mote the carcinogenic effects of various procarcino-
gens but that they alone are not intrinsically carcino-
genic (38-41). With such a hypothesis in mind. 
Wanless et al. (42) recently studied the diethylnitro-
samine-pretreated rat model. In these experiments it 
was shown that estrogens promote the development 
of hepatic neoplasm by a mechanism which involves 
increasing the mitogenic activity of the hepatocyte 
nucleus. It should be noted, however, that the dosage 
of estrogen used in these experiments was ZOO-fold 
greater than that used clinically. 
On the other hand, the biological importance of 
the estrogens in the process of malignant transforma-
tion of hepatic tumors has been questioned by Mish-
kin et al. (43). These authors show that administra-
tion of estrogen and tamoxifen in combination 
results in a reversal of acetylaminofluorine-induced 
hepatic hypertrophy, nodular proliferation, and ma-
lignant transformation. These chemically induced 
nodules before estrogen treatment displayed de-
creased estrogen receptor levels as compared with 
normal liver; however, the effects of the subsequent 
estrogen treatment on receptor levels were not eluci-
dated. It is generally conceded that hormone recep-
tors are necessary for the maintenance of hormone 
June 1984 
dependency. At this time, however we are uncertain 
as to which factors control receptor levels, and 
further, what role these receptors play in the disease 
process. 
Therefore, it may be premature to explain the 
relationship, if one exists, between the estrogen 
binding capacity of normal liver and experimental 
tumor or experimental estrogen-induced tumors. It is 
possible that the estrogen receptor is essential for 
participation in the early events of tumor formation, 
but that in later stages the estrogen, through its 
receptor, no longer exerts an influence on the cell. 
The present study clearly establishes that the Morris 
hepatic tumor does not have an increased estrogen 
receptor capacity or increased affinity for estrogens 
compared with normal rat liver. In contrast. the data 
clearly document reduced (p < 0.001) or no receptor 
binding activity by the tumor as compared with 
normal tissues. The lack of receptors in the trans-
plantable Morris hepatoma 7777 may represent an 
endpoint of dedifferentiation in this tissue. In fact, 
estrogen receptors have been detected in human 
adenoma. but at a level significantly lower than in 
normal tissue from the same liver (44). Further 
studies are necessary to confirm such a temporal 
relationship. 
The estrogen binder that is present in hepatoma 
cytosol but not in protamine sulfate precipitates or 
normal liver is interesting. This estrogen binder has 
properties that suggested that it may be AFP. Its 
molecular weight is comparable to AFP (45,46) and 
its specificity is such that DES does not compete for 
E2 binding, unlike the classic estrogen receptor (47). 
We have confirmed its identity by its selective im-
munoprecipitation by antiserum to AFP. These stud-
ies, however. also point to a necessary caution; 
estrogen binding in unfractionated liver cytosol, 
particularly in abnormal tissue, does not necessarily 
indicate the presence of an estrogen receptor. It is 
essential to establish the presence of receptor by 
criteria other than simply its ability to bind estrogen. 
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